Braskem 3Q26: R$3.37B Nine-Month Profit, But Auditor Flags Going-Concern Doubt
BAK sits 52% above its 52-week low of $0.743.
Summary
Braskem posted a R$3,374 million nine-month profit on FX and derivative gains, but the 3Q26 statements carry a going-concern emphasis: negative equity of R$14,213 million, negative working capital of R$50,611 million and negative operating cash flow of R$3,238 million while restructuring negotiations continue.
Key Events · Earnings and Guidance · BAK
-
Nine-Month Profit Driven by FX Gains
Consolidated net revenue was R$56,787 million and net profit R$3,374 million (R$3,703 million to shareholders), versus R$68 million a year earlier; the swing came largely from R$3,629 million of net derivatives and exchange-rate variations, while financial expenses of R$5,118 million exceeded gross profit of R$8,418 million.
-
Auditor Flags Going-Concern Uncertainty
Deloitte's review report includes an emphasis of matter citing negative shareholders' equity of R$14,213 million consolidated (R$13,616 million parent), negative net working capital of R$50,611 million consolidated and negative operating cash flow of R$3,238 million consolidated.
-
Debt Reclassified to Current Liabilities
Borrowings and debentures jumped to R$52,400 million in current liabilities from R$8,268 million at Dec/25 after covenant non-compliance and cross-default triggers; cash and equivalents fell to R$6,010 million from R$10,501 million.
-
Restructurings Await Creditor and Court Sign-Off
The out-of-court plan covers about R$56.4 billion (US$10.9 billion) of unsecured claims and needs accession above half plus court ratification; Braskem Idesa's prepackaged Chapter 11 plan was confirmed at the 09/22/2026 hearing, with ~R$8,165 million (US$1,576 million) of 9.25% Exit Notes and Braskem Group's stake falling from 75% to 58.33% on the Effective Date.
Analysis · BAK · Industrial Applications And Services
Braskem's 3Q26 report shows a swing to a R$3,374 million nine-month profit from R$68 million a year earlier, driven mainly by R$3,629 million of net derivatives and FX gains rather than operations — gross profit of R$8,418 million still does not cover R$5,118 million of financial expenses. The balance sheet is the real story: consolidated shareholders' equity is negative R$14,213 million, net working capital is negative R$50,611 million after R$52,400 million of borrowings were pushed into current liabilities, and operating cash flow was negative R$3,238 million. Deloitte's review carries an explicit going-concern emphasis, and the out-of-court restructuring still needs creditor accession above half of the R$56.4 billion subject claims plus court ratification, while Braskem Idesa's Chapter 11 plan awaits its Effective Date. Cash fell to R$6,010 million from R$10,501 million, and a US$950 million stand-by facility matures in December 2026 — the near-term liquidity test.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BAK was trading at $1.13 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $479M. The 52-week trading range was $0.74 to $5.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.